Clinical Trial: Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional

Official Title: Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia

Brief Summary: The purpose of this study is to test the safety and efficacy of fondaparinux in patients with heparin-induced thrombocytopenia (HIT). The primary objective is to ensure that patients with HIT who are treated with fondaparinux experience a prompt and complete recovery of their platelet count, and the secondary objective is to determine if any new blood clots are formed while receiving the fondaparinux and up to one month after study enrollment. This information will be compared to a historical control.

Detailed Summary:
Sponsor: Methodist Healthcare

Current Primary Outcome: Platelet count recovery [ Time Frame: 5 days ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Recurrent thromboembolic complications [ Time Frame: 4 weeks ]

Original Secondary Outcome: Same as current

Information By: Methodist Healthcare

Dates:
Date Received: January 4, 2008
Date Started: January 2008
Date Completion:
Last Updated: September 12, 2016
Last Verified: June 2009